Sino Biopharmaceutical Limited
1177
Clasificación en acciones
#1794
Sino Biopharmaceutical Limited, an investment holding company, operates as a... Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People’s Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company offers oncology medicines, including anlotinib hydrochloride capsules under Focus V brand, penpulimab injection under Annike brand, efbemalenograstin alfa injection under Yilishu brand, benmelstobart injection under Andewei brand, unecritinib fumarate capsules under Anboni brand, envonalkib citrate capsule under Anluoqing brand, garsorasib tablets under Anfangning brand, bevacizumab injection under Anbeisi brand, rituximab injection under Delituo brand, trastuzumab for injection under Saituo brand, and pertuzumab injection, under Paletan brand; liver disease medications, such as magnesium isoglycyrrhizinate injection under Tianqing Ganmei brand and entecavir dispersible tablets under Runzhong brand; and respiratory system medicines comprising budesonide suspension for inhalation under Tianqing suchang brand, and colistimethate sodium for injection under Tianyun brand. It also provides surgery/analgesia medicines, including flurbiprofen cataplasms under the brand Zepolas, limaprost tablets under the brand Kailitong, and recombinant human coagulation factor VIII for injection under the brand Anhengji. In addition, the company develops liver disease drugs, such as Lanifibranor and TQA2225; respiratory system drugs comprising TDI01, TQC2731, TCR1672, TQC3721, and TQH2722; and surgery/analgesia drugs, including PL-5, an antimicrobial peptide, TRD205, an AT2R inhibitor, and TRD303, a ropivacaine sustained-release solution. Further, it is involved in the long-term investments; and healthcare and hospital business. The company was incorporated in 2000 and is headquartered in Wan Chai, Hong Kong.
Precio por acción
$0.67161271
Última sincronización: 2026-10-16
Capitalización bursátil
$11.96B
Cambio (1 día)
-0.38%
Cambio (1 año)
-28.30%
País
HK
Comercio Sino Biopharmaceutical Limited (1177)
Categoría
Healthcare
Margen Operativo de Sino Biopharmaceutical Limited (1177)
Margen Operativo al October 2026 TTM: 29.76%
Según los informes financieros más recientes y el precio de las acciones de Sino Biopharmaceutical Limited, el margen operativo actual (TTM) es 29.76%. Al final de 2023, el margen operativo era 22.08%.
Historial de Margen Operativo de Sino Biopharmaceutical Limited desde 2000 hasta 2026
Margen Operativo al final de cada año
| Año | Margen Operativo | Cambiar |
|---|---|---|
| 2026 (TTM) | 29.76% | 39.98% |
| 2024 | 21.26% | -3.71% |
| 2023 | 22.08% | 2.89% |
| 2022 | 21.46% | 13.48% |
| 2021 | 18.91% | 6.66% |
| 2020 | 17.73% | -26.03% |
| 2019 | 23.97% | 0.67% |
| 2018 | 23.81% | -15.48% |
| 2017 | 28.17% | -15.33% |
| 2016 | 33.27% | 51.36% |
| 2015 | 21.98% | 8.49% |
| 2014 | 20.26% | -28.59% |
| 2013 | 28.37% | 31.46% |
| 2012 | 21.58% | 23.88% |
| 2011 | 17.42% | -34.98% |
| 2010 | 26.79% | 8.46% |
| 2009 | 24.70% | -7.49% |
| 2008 | 26.70% | -21.98% |
| 2007 | 34.22% | 5.72% |
| 2006 | 32.37% | 60.01% |
| 2005 | 20.23% | -20.07% |
| 2004 | 25.31% | 24.19% |
| 2003 | 20.38% | 3.19% |
| 2002 | 19.75% | -10.79% |
| 2001 | 22.14% | -1.29% |
| 2000 | 22.43% | 0.00% |
Margen Operativo de empresas similares o competidoras
| Empresa | Margen Operativo | Diferencia de Margen Operativo | País |
|---|---|---|---|
| 62.34% | -97.91% |
US
|
|
| 0.00% | - |
SE
|
|
| 0.00% | - |
FR
|
|
| 0.00% | - |
IT
|
|
| 0.77% | -99.97% |
US
|
¿Qué es el Margen Operativo de una empresa?
El Margen Operativo es un indicador clave para evaluar la rentabilidad de una empresa. Un margen operativo más alto suele ser mejor, ya que indica que una empresa puede vender sus productos o servicios por mucho más de lo que cuestan producirlos. Se calcula dividiendo las ganancias de la empresa entre sus ingresos.